You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 122 No. 11, November 1987 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, LONDON, APRIL 27 TO APRIL 30, 1987-PART I
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (18)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Estrogen Receptor Protein of Breast Cancer in Patients With Positive Nodes

High Recurrence Rates in the Postmenopausal Estrogen Receptor—Negative Group

David W. Kinne, MD; John A. Butler, MD; Marek Kimmel, PhD; Betty J. Flehinger, PhD; Celia Menendez-Botet, PhD; Morton Schwartz, PhD

Arch Surg. 1987;122(11):1303-1306.


Abstract



• In 448 patients with positive axillary lymph nodes who were treated with mastectomy at Memorial Sloan-Kettering Cancer Center, New York, from 1973 to 1978, estrogen receptor (ER) status was associated with survival. With a median follow-up of 75 months, significant differences were noted in the 288 postmenopausal patients; ER-positive patients had better six-year disease-free survival than ER-negative patients (60% vs 45%), as well as better overall survival. These differences were true in subgroups with one to three and four or more involved nodes. The addition of adjuvant systemic therapy had no significant effect on either ER-positive or ER-negative patients. The need for new imaginative systemic programs in the subgroup of ER-negative postmenopausal patients with breast cancer with positive nodes is apparent.

(Arch Surg 1987;122:1303-1306)



Author Affiliations



From the Breast Service, Department of Surgery (Dr Kinne), the Investigative Cytology Laboratory (Dr Kimmel), and the Department of Biochemistry (Drs Menendez-Botet and Schwartz), Memorial Sloan-Kettering Cancer Center, New York; the Department of Surgery, Harbor-UCLA Medical Center (Dr Butler); and the Department of Mathematical Sciences, IBM T. J. Watson Research Center, Yorktown Heights, New York (Dr Flehinger).


Footnotes



Accepted for publication July 16, 1987.

Read before the Annual Meeting of the Society of Surgical Oncology, London, April 28, 1987.

Reprints not available.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Unnecessary Axillary Surgery for Patients With Node-Negative Breast Cancer Undergoing Total Mastectomy
Olaya et al.
Arch Surg 2011;146:1029-1033.
ABSTRACT | FULL TEXT  

Biologic and Clinical Characteristics of Breast Cancer With Single Hormone Receptor Positive Phenotype
Rakha et al.
JCO 2007;25:4772-4778.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1987 American Medical Association. All Rights Reserved.